Blog

Yakup Ergün: PRODIGE 23: Long-term results

Photo of Yakup Ergün from batmanpetrol.com

Jul 8, 2024, 19:24

Yakup Ergün: PRODIGE 23: Long-term results

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared insight about a study by Thierry Conroy et al. on X:

“PRODIGE 23: Long-term results

Neoadj FOLFIRINOX vs SoC (CRT)

7y-DFS: 67.6 vs 62.5%
7y-MFS:79.2 vs 72.3%
7y-OS:81.9 vs76.1%

Induction chemotherapy with mFOLFIRINOX improves OS in LARC patients.”

Yakup Ergün: PRODIGE 23: Long-term results

Read the article.
Source: Yakup Ergün/X

7-year disease-free survival 7-year metastasis-free survival 7-year overall survival Antalya City Hospital cancer Cancer research CRT induction chemotherapy LARC locally advanced rectal cancer long-term results medical oncology mFOLFIRINOX neoadjuvant FOLFIRINOX OncoDaily Oncology PRODIGE 23 Standard of Care Thierry Conroy Yakup Ergün

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage